Resumo

BAUTISTA-PARADA, Ileana Rocío  e  PUENTES-MANOSALVA, Fabián Eduardo. Ulcerative Colitis Induced by Secukinumab in the Treatment of Ankylosing Spondylitis. Rev. colomb. Gastroenterol. [online]. 2023, vol.38, n.1, pp.79-81.  Epub 07-Jun-2023. ISSN 0120-9957.  https://doi.org/10.22516/25007440.884.

Interleukin 17 (IL-17) inhibitors are approved for treating psoriasis, psoriatic arthropathy, and ankylosing spondylitis. IL-17 is involved in the pathogenesis of inflammatory bowel disease (IBD); however, paradoxical events have been reported using selective IL-17 inhibitors such as secukinumab, whose pathophysiological mechanisms have not been fully clarified. Although the incidence of IBD in this group of patients is low, the risk could be reduced by carefully assessing risk factors such as family history, gastrointestinal symptoms, and fecal calprotectin before starting treatment.

Palavras-chave : Secukinumab; ulcerative colitis; ankylosing spondylitis.

        · resumo em Espanhol     · texto em Inglês | Espanhol     · Inglês ( pdf )